The small intestine is a significant site of ulceration and bleeding induced by 35 nonsteroidal anti-inflammatory drugs (NSAIDs). The pathogenesis is poorly understood. 36
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used 59 drugs, because of their ability to alleviate pain and inflammation. However, the 60 gastrointestinal (GI) toxicity of these drugs remains a major limitation to their use. The 61 ulceration and bleeding produced by NSAIDs in the stomach and duodenum can be 62 significantly diminished by co-administration of inhibitors of gastric acid secretion, such 63 as proton pump inhibitors (PPIs) and histamine H 2 receptor antagonists (H 2 RAs) (38). 64
However, it has been clear for many years that these drugs offer no protection to the 65 small intestine, where significant NSAID-induced damage and bleeding occurs (1, 23). In 66 fact, emerging evidence indicates that inhibitors of gastric acid secretion significantly 67 worsen the small intestinal damage caused by NSAIDs (7, 23, 37, 55, 58, 63). Although 68 much recent research has focused on the lower intestinal damage caused by NSAIDs, 69 there are currently no proven-effective preventative or therapeutic regiments for NSAID-70 enteropathy (49). Consequently, individuals with chronic conditions such as 71 osteoarthritis and rheumatoid arthritis, which often require long-term NSAID use for 72 symptom relief, are without any viable options to prevent NSAID-induced small intestinal 73 injury and bleeding. This is a major clinical concern as lower GI complications are more 74 difficult to detect, more expensive to treat, and result in longer hospital stays and higher 75 mortality rates, compared to upper GI complications (23, 50) . 76
The mechanisms underlying NSAID-induced damage in the distal intestine are in 77 many ways distinct from those of NSAID-induced gastroduodenal damage (48). The 78 damaging effects of NSAIDs in the stomach and proximal duodenum are closely related 79 to their ability to suppress cyclooxygenase (COX) activity, and dependent upon the for the measurement of prostaglandin (PG)E 2 synthesis, as described previously (54). 156
The concentrations of PGE 2 in the supernatants were determined by ELISA. The PGE 2 and 157 TXB 2 ELISA kits were purchased from Cayman Chemical (Ann Arbor, MI, USA). 158
159

Biliary Excretion of Naproxen and ATB-346 160
Concentrations of naproxen and ATB-346 in bile collected from rats treated orally 161 twice-daily for 2 days (4 treatments in total) with naproxen-or ATB-346 rats were 162 measured by mass spectrometry/liquid chromatography, as described previously (7). 163
These measurements were carried out blindly by Nucro-Technics (Scarborough, ON, 164 Canada). The bile samples were collected as described above, at a time when plasma 165 concentrations of naproxen for the naproxen-treated and ATB-346-treated groups were 166 comparable (43.3 ± 3.3 and 46.0 ± 2.5 μg/mL, respectively). 167
168
Effects of NSAIDs and PPIs on Bile Cytotoxicity 169
Rats (n=5-6/group) were treated twice daily for a total of 9 days with 170 omeprazole, lansoprazole (each at 10 mg/kg i.p.), or vehicle (DMSO). The doses of the 171
PPIs were selected based on preliminary studies in which we examined their ability to 172 markedly suppress gastric acid secretion in rats over a 12 h period, as described . In some experiments, naproxen (10 mg/kg), ATB-346 (14.5 mg/kg), or 174 vehicle (DMSO/1% CMC; 5:95 ratio) was co-administered orally twice daily for the final 175 4.5 days. One hour after the final administration of drug or vehicle, the rats were 176 anaesthetized with sodium pentobarbital. The bile duct was cannulated and bile was 177 collected, as described above. The small intestine was then evaluated for damage, as 178 described above. The doses of naproxen and ATB-346 were selected because previous 179 studies demonstrated that they produced comparable suppression of adjuvant-induced 180 arthritis in rats, and suppressed systemic and small intestinal COX-1 and COX-2 activity to 181 the same extent (7). Previously we demonstrated that the doses of omeprazole and 182 lansoprazole administered in this study markedly suppressed gastric acid secretion by 183 the 5 th day of administration, when NSAID treatment was initiated (55). 
DNA Extraction and Polymerase Chain Reaction-Denaturing Gradient Gel 213
Electrophoresis 214
Bacterial DNA was extracted from jejunal contents as previously described (32). Hamilton, ON, Canada). Denaturing gradient gel electrophoresis (DGGE) was performed 220 using a DCode universal mutation system (Bio-Rad, Mississauga, ON, Canada). 221
Electrophoresis was conducted at 130 V at 60°C for 4.5 h. Gels were then stained with 222 SYBR Green (Molecular Probes, Eugene, OR, USA) and viewed by ultraviolet 223 transillumination. A scanned image of an electrophoretic gel was used to measure the 224 staining intensity of the fragments using Quantity One software (version 4-2; Bio-Rad 225 Laboratories). The intensity of fragments is expressed as a proportion (%) of the sum of 226 all fragments in the same lane of the gel. Similarities between bacterial profiles were 227 determined by using the Dice coefficient (13) and Ward algorithm (56). A majority, 228 unweighted-pair-group method with arithmetic mean (UPGMA) algorithm was used to 229 construct a multi-dimensional scaled tree based on a resampling strategy of 200 230
permutations. 231 232
Deep sequencing analysis of 16S rRNA with Illumina 233
The V3 region of the 16S rRNA gene was amplified as previously described (2) 234 with modifications (58). Following separation of products from primers and primer 235 dimers by electrophoresis on a 2% agarose gel, PCR products of the correct size were 236 recovered using a QIAquick gel extraction kit (Qiagen, Mississauga, ON, Canada). 237
Custom, in-house Perl scripts were developed to process the sequences after Illumina 238 sequencing (58). Cutadapt (28) was used to trim any over-read, and paired-end 239 sequences were aligned with PANDAseq (30) with a 0.7 quality threshold. If a mismatch 240 in the assembly of a specific set of paired-end sequences was discovered, they wereBlackler et al. -11 culled. Additionally, any sequences with ambiguous base calls were also discarded. 242
Operational taxonomic units (OTUs) were picked using AbundantOTU+, and sequences 243 were clustered to 97% sequence identity operational taxonomic units (OTUs). Taxonomy  244 was assigned at a 0.8 threshold using the Ribosomal Database Project (RDP) (10) 245 classifier v.2.2 trained against the Greengenes SSU database (February, 2011 release). 246
For all downstream analyses we filtered the obtained OTU table excluding "Root" and 247 excluding any sequence that was not present at least 3 times across the entire dataset. 
Statistical Analysis 256
Rats were randomly assigned to the treatment groups and all analyses were 257 performed blindly. The specific statistical analyses used are described in each figure  258 legend. An associated probability of less than 5% was considered significant. 259
260
RESULTS 261
Naproxen-Induced Enteropathy 262
Rats treated with naproxen (30 mg/kg) twice daily for 2 days resulted in severe 263 intestinal ulceration (Fig. 1A) . There was negligible intestinal damage in rats treated with naproxen at 3 or 10 mg/kg. None of the doses of ATB-346 produced significant 265 small intestinal damage. 266
Consistent with the small intestinal damage, twice daily naproxen administration 267 for 2 days resulted in a dose-dependent increase in granulocyte infiltration (MPO 268 activity; Fig. 1B) into the jejunal tissue. In contrast, ATB-346 administration did not alter 269 MPO activity at any of the tested doses (Fig. 1B) . 270 271
Suppression of Cyclooxygenase Activity 272
Naproxen (10 mg/kg) administration suppressed systemic COX-1 activity (whole 273 blood thromboxane synthesis) by 98% and intestinal PGE 2 synthesis by 96% after twice 274 daily dosing for 2 days (Fig. 2 ). An equimolar dose of ATB-346 produced a comparable 275 level of suppression of whole blood thromboxane synthesis and intestinal PGE 2 276 synthesis. With 4 days of administration of the drugs the level of suppression of whole 277 blood thromboxane synthesis and intestinal PGE 2 synthesis rose to >99% and >97%, 278 respectively, for both naproxen and ATB-346. 279 280
Naproxen, but not ATB-346, Increased the Cytotoxicity of Bile 281
Bile collected from rats that had been treated with naproxen twice daily for 2 282 days exhibited a clear dose-dependent increase in cytotoxicity in the IEC-6 intestinal 283 epithelial cell assay, as compared to bile from vehicle-treated rats ( Figure 3A) . However, 284 bile collected from rats treated with ATB-346 at equimolar doses to naproxen, did not 285 exhibit any enhancement of cytotoxicity as compared to that from vehicle-treated rats. 286
The cytotoxicity of bile from naproxen-treated rats increased further when the bile wasBlackler et al. -13 from rats treated for 4 days rather than for 2 days, while bile from rats treated with ATB-288 346 for 4 days continued to show no increase in cytotoxicity (data not shown). 289
The effects of direct addition of naproxen into samples of bile on cytotoxicity 290 were also assessed. Bile spiked with naproxen at 1 or 5 μg/mL exhibited no significant 291 increase in cytotoxicity versus that seen with bile alone (data not shown). These 292 concentrations bracket those that were detected in bile from rats treated with naproxen 293 (see below). 294 295
Biliary Levels of Naproxen and ATB-346 296
There were dramatic differences in the concentrations of naproxen in bile 297 collected from rats 3 h after the final administration of naproxen or ATB-346 (Fig. 3B) . In 298 naproxen-treated rats the concentrations of naproxen in bile increased in a dose-299 dependent manner (to ~5 μg/mL at the highest dose), and were significantly greater 300 than the concentrations of naproxen in bile from rats treated with equimolar doses of 301 ATB-346 (Fig. 3B) . In contrast, treatment of rats with equimolar doses of ATB-346 302 resulted in markedly lower levels of naproxen in bile. ATB-346 was not detected in any 303
samples. 304 305
Effects of Naproxen and ATB-346 on Intestinal Microbiota 306
Administration of naproxen (10 mg/kg), ATB-346 (14.5 mg/kg) or vehicle twice 307 daily for 4 days altered the taxonomic composition of the jejunal microbiota in rats, as 308 analyzed by partial 16S rRNA gene profiling using Illumina sequencing. In particular, 309 naproxen induced a decrease in unclassified genera within the Lachnospiraceae family Lactobacillaceae family (Figure 4) . 314
In a separate experiment, rats were treated with a higher dose of naproxen (20 315
higher abundances of several gram-negative microbial families (see Table 1 ). Naproxen 320 administration also caused a significant decrease in the relative abundance of 321 unclassified bacteria within the Lachnospiraceae family (p<0.05). 322
323
PPIs Exacerbated Intestinal Injury and Inflammation 324
Treatment of rats with naproxen at a dose below the threshold for inducing 325 macroscopic intestinal ulcers did not cause significant inflammation, as measured by 326 jejunal MPO activity. Treatment with a PPI also did not cause significant intestinal 327 inflammation. However, co-treatment with naproxen and PPIs exhibited significant 328 intestinal inflammation (p<0.05 Fig. 5A ). This was observed with both omeprazole and 329 lansoprazole. In contrast, administration of ATB-346 (14.5 mg/kg) for 4 days did not 330 significantly affect jejunal levels of granulocyte infiltration when give alone, or when co-331 administered with a PPI (omeprazole) ( Figure 5B
As described above, bile collected from rats treated twice daily for 4 days with 335 naproxen (10 mg/kg) had enhanced cytotoxic effects compared to bile collected from 336 rats treated with vehicle ( Figure 5C ). In rats co-treated with naproxen and a PPI, a 337 significant increase in the cytotoxic effects of bile was observed as compared to bile 338 from rats treated with naproxen alone (p<0.01). Bile collected from rats treated with an 339 equimolar dose of ATB-346 exhibited similar cytotoxicity to bile collected from rats 340 treated with vehicle, and this was not significantly affected by co-administration of 341 omeprazole (Fig. 5D) . 342
343
PPIs Caused Intestinal Dysbiosis and Altered Luminal pH 344
Previous studies suggested that treatment of rats with omeprazole resulted in 345 significant changes in the intestinal microbiota, particularly a marked decrease in 346 Actinobacteria (Bifidobacter spp.) (55). This was further investigated in the present 347 study, using omeprazole and lansoprazole. Treatment of rats with omeprazole or 348 lansoprazole for 9 days resulted in a marked shift in the composition of the intestinal 349 bacterial community. As shown in Figure 6A The ability of treatment with either of the PPIs to markedly increase the 356 cytotoxicity of bile was recapitulated in this experiment (Fig. 6C) . Moreover, there were 357 significant changes in the pH of the intestinal luminal contents in rats treated with 358 omeprazole or lansoprazole as compared to that of vehicle-treated rats (Fig. 6D). 359 Surprisingly, treatment with either of the PPIs resulted in a significant decrease in jejunal 360 luminal pH. 361
To further investigate how PPI administration altered the intestinal microbiota in 362 rats, we analyzed the taxonomic composition of the jejunal microbiota in rats by partial 363 16S rRNA gene profiling using Illumina sequencing. The Firmicutes phylum, specifically 364 the Lactobacillaceae family, represented the vast majority (>95%) of bacterial 365 abundance in jejunal microbiota samples in both PPI-and vehicle-treated rats. 366
Administration of omeprazole or lansoprazole (each at 10 mg/kg) twice daily for 9 days 367 resulted in a significant (p<0.05) increases in abundance of γ-Proteobacteria (Fig.7) , 368 including the families Pseudomonadaceae and Enterobacteriaceae, compared to vehicle-369 treated rats. Omeprazole-treated rats exhibited a significant (p<0.05) decrease in the 370 abundance of Actinobacteria compared to vehicle-treated rats, while lansoprazole 371 treatment increased the relative abundance of Bacteroidetes (Fig. 7) . 372 373 374 375 376 DISCUSSION 377 378
The GI toxicity of NSAIDs remains the major limitation to the use of this class of 379 drugs. The mechanisms of NSAID-induced damage in the stomach and proximal 380 duodenum are well understood (47) and that damage can largely be prevented by the
Blackler et al. -17 co-administration of inhibitors of gastric acid secretion, such as PPIs or H 2 RAs (23, 38). 382
Conversely, the complex pathogenesis of NSAID-induced damage in the more distal 383 intestine remains incompletely understood and there are no proven-effective 384 preventative or curative treatments (49). Moreover, it is becoming apparent that 385 inhibitors of gastric acid secretion can significantly worsen NSAID-enteropathy (37, 55, 386
58). Considerable evidence indicates that interactions among bile, intestinal microbes 387
and the enterohepatic circulation of NSAIDs are important contributors to the 388 development of NSAID-induced intestinal damage (49). In recent years, it has been 389 demonstrated that H 2 S is a particularly potent cytoprotective agent in the GI tract (52). 390
Indeed, an H 2 S-releasing derivative of naproxen (ATB-346) was previously shown to 391 spare the rat gastrointestinal tract of damage, while the parent drug caused extensive 392 mucosal injury and bleeding (7, 53). 393
In the present study, administration of a commonly prescribed NSAID (naproxen) 394 dose-dependently caused intestinal ulceration and inflammation in rats. Naproxen is 395 excreted in bile and undergoes extensive enterohepatic circulation. Treatment with 396 naproxen significantly increased the cytotoxic effects of bile on cultured intestinal 397 epithelial cells, consistent with effects seen with other NSAIDs in similar models (12, 64) . 398
TIn contrast to the effects of naproxen, treatment of rats with ATB-346, an H 2 S-releasing 399 derivative of naproxen, did not elicit intestinal damage or inflammation. Treatment with 400 ATB-346 also did not increase the cytotoxicity of bile on cultured intestinal epithelial 401 cells. Interestingly, although ATB-346 is metabolized to naproxen, the levels of naproxen 402 in bile from ATB-346-treated rats were substantially lower than those observed in rats 403
Blackler et al. -18 treated with an equimolar dose of naproxen, despite plasma levels of naproxen being 404 comparable in the two groups. 405
The enterohepatic recirculation of NSAIDs is a major factor contributing to the 406 intestinal damage caused by these drugs (3, 9, 35, 42, 59 ). When NSAIDs undergo 407 enterohepatic recirculation, the intestinal epithelial cells are repeatedly exposed to the 408 topical damaging effects of the NSAID and its metabolites ( increase its cytotoxicity is consistent with previous studies suggesting that it is the 415 naproxen-glucuronides secreted in bile that account for the increased damage it causes 416 to intestinal epithelial cells (39) . However, the enhancement of bile cytotoxicity following 417 naproxen administration may also be related to changes in the composition of bile itself. The present study also explored the mechanisms underlying the exacerbation of 446 NSAID-enteropathy by PPIs. As mentioned above, inhibition of gastric acid secretion can 447 lead to significant dysbiosis (40, 41, 55), and this was also shown to underlie a significant 448 increase in susceptibility to intestinal damage in rats treated with PPIs (55) jejunal microbiota that were observed, but we cannot rule out the possibility that the 463 altered pH was a consequence of the changes in the microbiota. 464 PPI treatment also resulted in a marked enhancement of bile cytotoxicity, which 465 may account in part for the exacerbation of intestinal damage in rats co-treated with 466 naproxen and a PPI. We previously reported that the cytotoxicity of bile is increased by 467 H 2 RAs (5), and exacerbation of intestinal damage is observed with the combination of 468 
